Treatment outcome of new culture positive pulmonary tuberculosis in Norway

The key elements in tuberculosis (TB) control are to detect the disease as early as possible and to ensure that those diagnosed complete their treatment and get cured. The World Health Organization (WHO) target for treatment success is 85 percent of all detected smear-positive cases [1]. Even where free medication is available, many patients are not successfully treated [2, 3]. Main reasons for non-success are death (while on treatment or before start of treatment) and loss to follow-up. Incomplete treatment may result in prolonged excretion of bacteria that may also acquire drug resistance, cause transmission of disease and lead to increased morbidity and mortality [4].

Norway has about 4.5 million inhabitants, with foreign-born residents comprising 6.9% of the total population in 2002. The proportion of TB cases from foreign-born residents has increased from 19 % in 1986 to 76 % in 2002 [5]. However, the total number of cases has remained relatively stable. The reporting of treatment outcome for all TB cases has been obligatory since 1996. A study on treatment outcome for culture positive pulmonary TB in Norway in 1995 showed a high death rate and a high rate of loss to follow-up. Only 76% of patients who were included in that study completed treatment [6]. While the incidence rate of TB is low in Norway compared to most countries in the world, challenges still remain in achieving the WHO target for treatment success. However, there are some problems with the WHO definition of success rate and other measures have been proposed. A working group from the WHO, the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Royal Netherlands Tuberculosis Association (KNCV) have defined a reasonable target for treatment outcome in low-incidence countries as to reduce the proportion of patients with a potentially bacteriologically unsuccessful outcome (failure, default, transfer) to less than 10% [7].

The aims of this study were to evaluate the treatment outcome for new culture positive pulmonary TB cases registered in Norway during the period 1996–2002, and to identify factors associated with non-successful treatment.

In our study, the proportion of patients with a potentially bacteriologically unsuccessful outcome (failure, default, transfer) was 8%.

The average duration of residence in Norway for foreign-born patients at TB registration was 3.8 (range 1–31) years. There were no differences in the treatment success rates for those who had lived in Norway for less than three years and for those who had stayed longer than three years.

Among the 22 patients who defaulted treatment (3%) (table 1), four had MDR-TB and three additional patients had isolated INH resistant strains at the start of the treatment. The default rate was higher among foreign-born and male patients.

There were 26 patients (4%) who were transferred out (table 1). Of these, 21 were reported in 2000–2002. All of them have left the country. Twenty-two were on treatment when they left the country and four had not started treatment. Among the 26, seven were expelled from the country. Six of these were on treatment and one had not started treatment at the time of expulsion. For those who left the country while on treatment, the average duration of treatment was 78 days. Twelve of them had treatment only for two months or less. Of the 26 patients who were transferred out, three had isolated INH resistant strains and one had MDR-TB when they left the country.

There was no systematic registration of TB/ human immunodeficiency virus (HIV) co-infection at the TB Registry. For those who died while on treatment or before treatment started, HIV disease was registered as the cause of death for two patients (table 2).

Susceptibility testing for the main TB drugs was done in most of the patients. However, susceptibility testing for streptomycin was done for fewer patients than other main TB drugs. Resistance to INH and streptomycin was most common, and resistance was frequent among foreign-born patients. Of those with MDR-TB, two were born in Norway and eight abroad.

Of the 655 patients included in this study, 453 were detected through passive case finding (due to their symptoms). Another 101 patients were discovered through the immigration TB screening program. A total of 52 patients were detected through following ups of close contacts of identified infectious cases (22 cases) and of previous abnormal mass miniature radiology (MMR) (32 cases). The remainder was discovered through other screening programs. No information on mode of detection was available for three patients.

In our study, the total treatment success rate for new culture positive pulmonary TB for the period 1996–2002 was 83%. This is close to the WHO target of success rate of 85% of all smear positive cases. However, subgroups of patients contributing to low success rate warrant special attention such as those who defaulted treatment, those who were transferred out and those who died. The first two subgroups mainly comprise patients who were born abroad and the last subgroup mainly comprises patients who were born in Norway. Despite these problems, Norway has reached the reasonable target for treatment outcome in low-incidence countries [7].

Our study shows a default rate of 3%. Higher default rates have been described in other studies such as Vaud County, Switzerland (16%) [2], Hamburg, Germany (10%) [12], and Sweden (7%) [3]. Although the default rate in Norway is lower than in these countries, some of the patients who defaulted treatment, including patients with MDR-TB, have been the cause of small on-going outbreaks [13]. Default can constitute a major public health problem. Although incomplete treatment can prevent patients from dying from TB, the patients may remain infectious and even develop MDR-TB. It is therefore worrying that several patients in our study who defaulted treatment had isolated INH resistant strains or MDR-TB prior to treatment. Language problems, lack of understanding of the patients' cultural background, lack of communication between primary health care and hospitals, frequent change of address and stigma related to TB might be some of the reasons for defaulting. DOT was used on an individual basis during the study period, especially when an increased risk of non-adherence was suspected, but it became mandatory in Norway from 2003 according to the new TB regulations [14]. Adoption of this strategy will hopefully improve treatment adherence further.

In the transferred out group, the majority of patients left the country on their own initiative, but seven were expelled. Most of the patients who left the country were on treatment, but we do not have information about their treatment outcome. It is worrying that some of the patients who were expelled moved to countries with political unrest and poorly functioning TB programs. In this group three patients already had isolated INH resistant strains and one had MDR-TB. Expelling patients with TB before completion of treatment is unfortunate, unless it can be guaranteed that adequate treatment will be provided elsewhere. Efforts should be made to ensure the continuity of treatment for patients who move out of the country and, if possible, to allow them to start and complete their treatment, even if they have to leave the country later. The Netherlands have adopted a system where patients are not expelled from the country as long as they are on treatment. According to the new Norwegian manual for TB control and prevention [11], health personnel should encourage patients who are at risk to be expelled from the country to inform the Norwegian Directorate of Immigration through their legal representatives about their disease, and they may then be allowed to stay until treatment is completed. However, we believe there is a need for more awareness among health personnel, immigration authorities, the police and the legal representatives of the patients about this possibility.

The death rate in our study was 9%. Other studies from low TB incidence regions of the world showed death rates among TB patients of 24%, 14% and 6% in Baltimore City, USA [15], Vaud County, Switzerland [2] and Hamburg, Germany [12] respectively. Common for these studies and our study is that most patients who died were old, and many of them also had other illnesses. But if we only include only patients who started treatment, the actual death rate for our study was 6%. When considering the treatment outcome of TB, many studies including ours, include patients who never started treatment. This might seem contradictory, but it is an important issue that shows a deficiency in TB control. This is also in line with the recommendations of a working group of the WHO and the European Region of the IUATLD for uniform reporting by cohort analysis of treatment outcome in TB patients [16]. It has been suggested that acceptable treatment success rates need to be revised under such circumstances. It is difficult to know to what extent the death of the nine patients whose only cause of death was TB could have been prevented. Diagnosis of pulmonary TB can be especially difficult in older patients with co-existing illness. In one study, it was suggested that treatment of latent TB in such high risk elderly patients should be a high priority although advanced age is a relative contraindication [17]. Other studies recommend the start of anti-TB treatment on suspicion whilst awaiting results of diagnostic tests in elderly patients, provided there is no other obvious cause of their illness [18, 19]. This makes sense as our study shows that 19 patients died before treatment start and four of them were diagnosed at autopsy. Two studies from Canada [20] and former Yugoslavia [21] have concluded that delay in diagnosis of TB was the main factor contributing to death from TB. Delay in diagnosis is outside the scope of this study. But autopsy rates in Norway are low [18] and therefore it is likely that there is under-diagnosis of deaths due to TB.

As indicated in the results section, TB/HIV co-infection is not a common cause of death for TB patients in Norway as most of the patients born in Norway were elderly persons with low risk of HIV and most foreign-born patients were from countries with low levels of HIV infection [22]. Therefore, we believe that it had a minor impact on the treatment outcome.

In the logistic regression model, increasing age and INH resistance were significant risk factors for non-successful treatment. We expected to find that age played a role, since old age in itself will contribute towards higher mortality, partly through co-existing illness. INH is a powerful bactericidal drug and resistance to the drug might reduce the effectiveness of standard short-course treatment [23]. Treatment was fairly standardized even in the previous TB manual from 1996: Four drugs to all foreign-born and to all previously treated TB patients and three drugs to patients born in Norway who were not likely to have been infected with drug resistant strains abroad. However, an analysis made by the National TB register in 1999 showed that only 75% of foreign-born patients received four drugs at the start of their treatment (Heldal E, personal communication, National TB Registry of Norway).

Although the TB treatment success rate in Norway has increased compared to previous studies and although it has reached a reasonable target for treatment outcome in low-incidence countries, the total success rate for 1996–2002 was still slightly below the WHO target of success rate of 85%. Early diagnosis of TB in elderly patients to reduce the death rate, abstaining from expulsion of patients on treatment and further measures to prevent default could improve the success rate further.